Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IOVA Iovance Biotherapeutics Inc
- Stocks
- Healthcare
- NASDAQ: IOVA
Price (delayed)
$1.83
Market cap
$611.1M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.23
Enterprise value
$486.77M
Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy
Highlights
Iovance Biotherapeutics's debt has decreased by 36% YoY and by 8% from the previous quarter
The EPS has grown by 32% YoY and by 3.9% from the previous quarter
The company's gross margin has surged by 103% YoY but it fell by 11% QoQ
The company's quick ratio fell by 18% YoY but it rose by 9% QoQ
Key stats
What are the main financial stats of IOVA
Market
Valuations
Earnings
Shares outstanding
333.93M
Market cap
$611.1M
Enterprise value
$486.77M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.78
Price to sales (P/S)
2.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.29
Revenue
$212.68M
Gross profit
$46.2M
Operating income
-$398.78M
Net income
-$375.36M
EBIT
-$378.62M
EBITDA
-$333.86M
Free cash flow
-$347.5M
Per share
Balance sheet
Liquidity
EPS
-$1.23
EPS diluted
-$1.23
Free cash flow per share
-$1.08
Book value per share
$2.34
Revenue per share
$0.66
TBVPS
$2.11
Total assets
$966.74M
Total liabilities
$198.88M
Debt
$53.72M
Equity
$767.87M
Working capital
$389.96M
Debt to equity
0.07
Current ratio
4.18
Quick ratio
3.56
Net debt/EBITDA
0.37
Margins
Efficiency
Dividend
EBITDA margin
-157%
Gross margin
21.7%
Net margin
-176.5%
Operating margin
-187.5%
Return on assets
-39.2%
Return on equity
-49.7%
Return on invested capital
-85.4%
Return on capital employed
-44.9%
Return on sales
-178%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IOVA stock price
How has the Iovance Biotherapeutics stock price performed over time
Intraday
0.55%
1 week
4.57%
1 month
-47.71%
1 year
-77.41%
YTD
-75.27%
QTD
-45.05%
Financial performance
How have Iovance Biotherapeutics's revenue and profit performed over time
Revenue
$212.68M
Gross profit
$46.2M
Operating income
-$398.78M
Net income
-$375.36M
Gross margin
21.7%
Net margin
-176.5%
The company's gross margin has surged by 103% YoY but it fell by 11% QoQ
Iovance Biotherapeutics's net margin has soared by 99% YoY and by 22% from the previous quarter
The operating margin has soared by 99% YoY and by 22% from the previous quarter
IOVA's revenue is up by 30% QoQ
Price vs fundamentals
How does IOVA's price correlate with its fundamentals
Growth
What is Iovance Biotherapeutics's growth rate over time
Valuation
What is Iovance Biotherapeutics stock price valuation
P/E
N/A
P/B
0.78
P/S
2.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.29
The EPS has grown by 32% YoY and by 3.9% from the previous quarter
IOVA's price to book (P/B) is 82% less than its 5-year quarterly average of 4.3 and 72% less than its last 4 quarters average of 2.8
IOVA's equity is up by 13% year-on-year and by 8% since the previous quarter
The price to sales (P/S) is 91% lower than the last 4 quarters average of 29.8
IOVA's revenue is up by 30% QoQ
Efficiency
How efficient is Iovance Biotherapeutics business performance
The ROS has soared by 99% YoY and by 22% from the previous quarter
Iovance Biotherapeutics's ROIC has increased by 40% YoY
The ROE is up by 30% year-on-year and by 2.2% since the previous quarter
The return on assets has increased by 29% year-on-year
Dividends
What is IOVA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IOVA.
Financial health
How did Iovance Biotherapeutics financials performed over time
The company's quick ratio fell by 18% YoY but it rose by 9% QoQ
The current ratio has increased by 12% from the previous quarter but it has decreased by 10% YoY
Iovance Biotherapeutics's debt is 93% less than its equity
IOVA's debt to equity is down by 42% YoY and by 13% from the previous quarter
Iovance Biotherapeutics's debt has decreased by 36% YoY and by 8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.